United States Kidney Cancer and Renal Cell Carcinoma Drugs Market to Reach USD 8.9 Billion by 2031, Growing at 6.3% CAGR | Roche Inc, GlaxoSmithKline Plc., Active Biotech Ab.

The Kidney Cancer and Renal Cell Carcinoma Drugs Market is anticipated to reach USD 8.9 billion by 2031 from USD 5.6 billion in 2022, at a CAGR of 6.3% during the forecast period.

Kidney cancer drugs primarily target Renal Cell Carcinoma (RCC), the most common form of kidney malignancy. Treatments include targeted therapies like tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors. These drugs work by blocking tumor growth pathways and enhancing immune response. Combinations of immunotherapy and targeted drugs have improved patient survival rates. Ongoing research explores biomarkers for personalized medicine and resistance mechanisms. Early diagnosis and advanced therapeutics are key to effective RCC management.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Kidney Cancer and Renal Cell Carcinoma Drugs Market Landscape:- https://datamintelligence.com/download-sample/kidney-cancer-and-renal-cell-carcinoma-drugs-market?Ranjith

☛ Kidney Cancer and Renal Cell Carcinoma Drugs Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In July 2025, Pfizer Inc. reported positive Phase 3 results for Inlyta (axitinib) combination therapy in advanced renal cell carcinoma, demonstrating improved progression-free survival and tolerability.

✅ In June 2025, Exelixis expanded its Cabometyx (cabozantinib) program to first-line treatment for metastatic RCC, highlighting efficacy in combination with immune checkpoint inhibitors.

✅ In May 2025, Bristol Myers Squibb initiated clinical trials for a novel PD-1/VEGF dual-targeted therapy, aimed at enhancing immune response and anti-angiogenic effects in RCC patients.

Japan: Recent Industry Developments

✅ In July 2025, Astellas Pharma advanced Phase 2 trials for a next-generation tyrosine kinase inhibitor (TKI) for localized and metastatic RCC, focusing on improved selectivity and reduced side effects.

✅ In June 2025, Daiichi Sankyo partnered with academic hospitals to evaluate antibody-drug conjugates (ADCs) for aggressive kidney cancers, exploring targeted delivery to tumor cells.

✅ In May 2025, Chugai Pharmaceutical launched a post-marketing surveillance program for combination immunotherapies in Japanese RCC patients, assessing long-term outcomes and safety profiles.

☛ Kidney Cancer and Renal Cell Carcinoma Drugs Market Competitive Landscape:

Roche Inc, GlaxoSmithKline Plc., Active Biotech Ab., Heidelberg Pharma AG, Inc., Bristol-Myers Squibb, Eisai, Exelixis, Novartis AG, Amgen, and Bayer AG among others.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/kidney-cancer-and-renal-cell-carcinoma-drugs-market?Ranjith

☛ Segments Covered in the Kidney Cancer and Renal Cell Carcinoma Drugs Market:

By Product Type: Bevacizumab, Everolimus, Cabozantinib, Axitinib, Sorafenib, Temsirolimus, Sunitinib.

By Distribution Channel: Hospital Pharmacy, Retail Pharmacies, Online Pharmacies, and Others.

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Kidney Cancer and Renal Cell Carcinoma Drugs Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=kidney-cancer-and-renal-cell-carcinoma-drugs-market?Ranjith

☛ Regional Analysis for Kidney Cancer and Renal Cell Carcinoma Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.